14th World Congress on Gastrointestinal Cancer
ESMO 14th World Congress on Gastrointestinal Cancer
Continuing Medical Education Opportunity
November 21, 2011, Imedex, LLC Presents: ESMO 14th World Congress on Gastrointestinal Cancer on 27-30 June 2012 in Barcelona, Spain. This oncology continuing medical education event will present a comprehensive overview of the latest advances and innovations in the gastrointestinal field.
The ESMO World Congress on Gastrointestinal Cancer is the world’s leading forum for practicing cancer research clinicians and specialists to stay abreast of the newest information and review forward-looking practices for the management of gastrointestinal cancer. Over 60 expert specialists will lead sessions and meet with participants in small targeted groups to address educational and practical advancements tht are tailored to the needs of their audience. Among the specialists will be Nadir Arber, MD, MSc, MHA, Andrés Cervantes, MD, PhD, Fortunato Ciardiello, MD, PhD, Mario Dicato, MD, Bengt Glimelius, MD, PhD, Richard M. Goldberg, MD, Axel Grothey, MD, Karin Haustermans, MD, PhD, Yoon-Koo Kang, MD, PhD, David J. Kerr, MD, FRCP, Roberto Labianca, MD, John L. Marshall, MD, Bernard Nordlinger, MD, Arnaud D. Roth, MD, Philippe Rougier, MD, PhD, Wolff Schmiegel, MD,PhD, Josep Tabernero, MD, PhD, Eric Van Cutsem, MD, PhD, Cornelius J.H. van de Velde, MD, PhD and John R. Zalcberg, MD, PhD. The World Congress will focus on personalized therapy, multidisciplinary management and unraveling molecular mechanisms. A broad range of experts will be in attendance, including a target audience of practicing clinicians, gastroenterologists, hepatologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers. Cutting-edge research will be at the core of this continuing medical education conference, and researchers and practitioners will be given the ability to interact with colleagues worldwide to share their best practices. Participants are strongly encouraged to submit their abstracts to be considered for presentation.
Upon completion of this continuing medical education conference, attendees should be able to:
• Identify and comment on current controversies in the management of patients with gastric or esophageal cancers
• Discuss contemporary treatment options for patients with gastric or esophageal cancers
• Specify available treatment options for rare gastrointestinal and neuroendocrine tumors
• Recognize the epidemiology and pathogenesis of hepatocellular carcinoma
• Deliberate the management of patients with cancer of the liver
• Understand adjuvant and neoadjuvant treatment options for patients with locally advanced and metastatic cancer of the pancreas
• Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer
• Generalize the use of molecular markers for screening and prognosis of colorectal cancer and gastric cancer
• Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
• Comment on and recognize new agents in the treatment of colorectal cancer and the latest clinical trials results
• Detect and adopt treatment strategies for rectal cancer
• Distinguish appropriate surgical techniques for the treatment of gastrointestinal cancers
This live gastroenteroogy CME webinar will be held on 27-30 June 2012
For more information and to register for the ESMO 14th World Congress on Gastrointestinal Cancer on 27-30 June 2012 please contact us:
E-mail us at registration@imedex.com
Call us toll-free at 1-855-276-6855
or
Register Online at http://worldgicancer.com/WCGI/WGIC2012/registration.asp
Great Debates and Updates in Thoracic Malignancies
Great Debates & Updates in Thoracic Malignancies
Continuing Medical Education Opportunity
SAN FRANCISCO, CA, November 21, 2011 – Imedex, LLC would like to present the Great Debates & Updates in Thoracic Malignancies meeting occurring on May 5, 2012 in San Francisco, California. The target audience for this oncology continuing medical education (CME) meeting is specifically designed for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and other physicians, clinicians, physicians-in-training, and health-care professionals (nurses, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with lung and other thoracic cancers.
This oncology continuing medical education opportunity will feature an interactive format that will allow speakers and audience members the ability to exchange information through a “hands-on” computerized speaker-audience interaction system. Participants attending this oncology CME meeting will be able to answer multiple-choice questions and the answers will be calculated and projected on a screen in tabular or graphic form for all to see. This system allows for attendees from diverse disciplines to see differing opinions and compare consensus between the speakers and each other.
After successful completion of this oncology CME opportunity, participants should be able to:
• Have increased knowledge regarding:
• Ongoing trials and novel approaches to adjuvant therapy for lung cancer
• Have increased confidence in their ability to:
• Manage advanced NSCLC in the frontline, maintenance, and salvage settings
• Manage resectable, high-risk, or inoperable lung cancer with single or combined modalities
• Increase the frequency (compared with current) with which they plan to:
• Use mutation status and other biomarkers to predict outcomes and select optimal treatments for each patient
• Enroll patients in clinical trials of novel agents or new indications for existing agents
For more information and to register for the Great Debates & Updates in Thoracic Malignancies meeting on May 5, 2012 in San Francisco, California please contact us:
Email us at registration@imedex.com
Call us toll-free at 1-855-276-6855
or
Register Online at http://www.greatdebatesinlungcancer.com/2012/index.asp
Congress on Myeloproliferative Neoplasm and Myelodysplastic Syndromes
European Focus on Myeloproliferative Neoplasms and
Myelodysplastic Syndromes
Continuing Medical Education Opportunity
LISBON, PORTUGAL, November 21, 2011 – Imedex, LLC would like to present the European Focus on Myeloproliferative Neoplams and Myelodysplatic Syndromes occurring on 4-5 May 2012 in Lisbon, Portugal. This continuing medical education (CME) will have a target audience of hematologists, oncologists, and other health-care professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians’ assistants, etc.) involved and/or interested in the therapeutic management of patients with myelodysplastic and myeloproliferative diseases.
This continuing medical education (CME) activity is the first of its kind in Europe that will focus on the latest advances in MPD, MDS and MPN. Attendees of this gastroenterology CME meeting will be able to network with nationally recognized leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, and promises to be a stimulating, interactive continuing medical education opportunity for attendees.
One of the goals of this CME meeting is to present the best new scientific research and advance knowledge on the state of the science.
Upon successful completion of this continuing medical education (CME) activity, participants should be able to:
• Have increased knowledge of the role of genetic mutations in prognosis and therapeutic decision-making for myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPDs)
• Have increased confidence in their ability to make risk-stratified treatment decisions for MDS and myelofibrosis (MF)
• Have increased confidence in their ability to evaluate current treatment options for MDS and MF, including stem cell transplant, chemotherapy, and targeted agents
• Have increased confidence in their ability to manage chronic MPNs such as essential thrombocythemia and polycythemia vera
• Be more likely to enroll patients in clinical trials of JAK inhibitors and other novel agents for MDS and MPDs
For more information and to register for the European Focus on Myeloproliferative Neoplasm and Myelodysplatic Syndromes on May 4-5, 2012 please contact us:
E-mail us at registration@imedex.com
Call us toll-free at 1-855-276-6855
or
Register Online at http://www.mpnsyndromescongress.com/2012/index.asp
Great Debates and Updates in Hematologic Malignancies
NEW YORK, NY, November 21, 2011 – Imedex, LLC would like to present the Great Debates and Updates in Hematologic Malignancies meeting occurring on April 27-28, 2012 in New York, New York. This oncology continuing medical education (CME) activity has a target audience of academic and community hematologists, oncologists, oncology nurses and other healthcare professionals involved and/or interested in the treatment of patients with hematologic malignancies.
This oncology CME conference will focus on controversial areas in the management of hematologic malignancies and will also cover a broad curriculum of hematologic malignancies, from lymphoma to leukemia to myeloma to myeloproliferative disorders. The format of this oncology CME conference will include didactic presentations, in conjunction with lively and interactive debates. During this oncology CME meeting, discussions between the faculty and audience members will be encouraged with a focus on how new information fits into current community practice, as attendees will have the chance to really engage themselves with an insightful look at more than one side of a question. Discussions will focus on how the new data fits into current community practice of hematology, and will be aimed at facilitating rapid incorporation of important new advances in treatment into the registrant’s current practice.
Upon successful completion of this continuing medical education opportunity, attendees should be able to:
• Have increased awareness of recent challenges to the standards of frontline and salvage therapy for hematologic malignancies
• Have increased confidence in their ability to use novel tools to predict patient outcomes and guide treatment planning for hematologic malignancies
• Have increased confidence in their ability to evaluate potential benefits and risks of maintenance therapy for hematologic malignancies
• Have increased confidence in their ability to recommend specific treatment strategies for elderly versus younger patients with hematologic malignancies
• Have increased confidence in their ability to manage comorbidities and treatment side effects in patients with hematologic malignancies
• Be more likely to incorporate new data from recent clinical studies into therapeutic decision-making for hematologic malignancies
For more information and to register for the Great Debates and Updates in Hematologic Malignancies meeting on April 27-28, 2012 in New York, New York please contact us:
E-mail us at registration@imedex.com
Call us toll-free at 1-855-276-6855
or
Register Online at http://www.greatdebatesinhematologicmalignancies.com/2012/index.asp
Great Debates and Updates in Gynecologic Malignancies
NEW YORK, NY, November 21, 2011 – Imedex, LLC would like to present the Great Debates & Updates in Gynecologic Malignancies meeting occurring on April 27-28, 2012 in New York, New York. The target audience for this continuing medical education (CME) activity is gynecologists, oncologists, and other physicians, clinicians, physicians-in-training, and healthcare professionals (including physician assistants and clinical nurse practitioners) involved in the diagnosis and management of gynecologic cancers including ovarian, uterine, and cervical cancers.
This oncology CME event will use didactic presentations in conjunction with lively and instructive debates to give practicing clinicians a thorough analysis of all currently available and emerging data. There will also be an interactive format feature that will allow speakers and audience members the ability to exchange information through a “hands-on” computerized speaker-audience interaction system. During this oncology CME event participants will be able to answer multiple-choice questions and the answers will be calculated and projected on a screen in tabular or graphic form for all to see. This system allows for attendees from diverse disciplines to see differing opinions and compare consensus between the speakers and each other.
For more information about this exciting oncology cme and to register for the Great Debates & Updates in Gynecologic Malignancies meetingon April 27-28, 2012 in New York, New York please contact us at:
Email us at registration@imedex.com
Call us toll-free at +1 (855) 276 6855
or
Online at http://greatdebatesingynecologicmalignancies.com/2012/index.asp
Great Debates in GI Malignancies
Great Debates And Updates In GI Malignancies
Continuing Medical Education Opportunity
NEW YORK, NY, November 21, 2011 – Imedex, LLC presents Great Debates and Updates in GI Malignancies occurring on March 30-31, 2012 in New York, New York. This continuing medical education (CME) opportunity has a target audience of gastrointestinal oncologists, medical oncologists, gastroenterologists, radiation oncologists, gastrointestinal surgeons, pathologists, and other physicians in active clinical practice involved and/or interested in the diagnosis, treatment, and management of patients with GI malignancies.
This oncology CME opportunity will feature a Meet the Experts lunch, which will allow attendees and faculty presenters the opportunity to interact during lunch on Friday and Saturday in a relaxed setting. During this gastroenterology CME meeting there will also be an audience participation opportunity that will allow speakers and the audience to exchange information through a “hands-on” computerized speaker-audience interaction system. This system will allow participants to answer multiple-choice questions, and within seconds, the answers are calculated and projected on a screen in tabular or graphic form for all to see. This system will allow attendees from diverse disciplines to see differing opinions and compare consensus between the speakers and each other.
Some topics for discussion during this oncology CME opportunity will include:
• Colorectal cancer
• Pancreatic cancer
• GIST
• Biliary tract cancer
• Neuroendocrine tumors
• Hepatocellular carcinoma
Upon successful completion of this continuing medical education opportunity, attendees should be able to:
• Demonstrate increased knowledge regarding:
o The significance and utilization of at least one prognostic or predictive biomarker in colorectal and gastric cancers
• Feel more confident in their ability to:
o Select a therapy based upon biomarker test analysis
o Discuss the current and future role of biologic and targeted therapies in managing GI cancers
o Recommend the most appropriate adjuvant or neoadjuvant therapy regimen for patients with GI cancer
o Summarize the role of radiotherapy in GI malignancies
o Recommend optimal therapeutic algorithms based upon current and emerging data
For more information and to register for Great Debates and Updates in GI Malignancies on March 30-31, 2012 in New York, New York please contact us:
E-mail us at registration@imedex.com
Call us at 1-678-242-0906
Or
Register online at http://www.greatdebatesingimalignancies.com/2012/index.asp
Great Debates in IBD
Great Debates And Updates In Inflammatory Bowel Diseases
Continuing Medical Education Opportunity
NEW YORK, NY, November 21, 2011 – Imedex, LLC would like to present the Great Debates And Updates In Inflammatory Bowel Diseases. Occurring in New York, New York this continuing medical education (CME) opportunity has a target audience of gastroenterologists, hospitalists, internists, physician assistants, nurses, surgeons, and other clinicians with an interest in treating patients with IBD inclusive of children, teens, and young adults.
This continuing medical education opportunity will focus on controversial areas in the management of patients with IBD, as nationally-recognized thought leaders take opposing sides on topics of interest to physicians and their patients.
Upon successful completion of this CME opportunity, participants should be able to:
• Review the standards and the use of clinical tools that can increase the accuracy of diagnosing IBDs
• Implement into practice the significant advances that have been made in biologics, immunomodulators, and combination therapy for the treatment of IBDs
• Identify current strategies to therapeutically manage naïve patients and patients that have not responded to therapy
• Summarize the role of vaccinations, bone monitoring, and cancer screening for healthcare maintenance of IBDs
• Use best practices related to the transition of care for the pediatric patient and provide the optimal therapeutic regimen for the growing child with IBD
• Review the major findings regarding the treatment of acute pediatric ulcerative colitis from the OSCI trial and their potential impact on current clinical practice
• Discuss optimal therapies during post-SONIC era for pediatric patients with IBDs
• Manage the effect that treatment of IBDs may have on fertility, pregnancy, and neonatal outcomes, and restate the treatment precautions for pregnant women
• Evaluate the present knowledge regarding risk stratification to improve quality of care for patients with IBDs
• Describe the utilization of disease activity indices to define treatment success in patients with IBDs
• Review the impact of biomarkers on guiding therapy decisions
For more information and to register for the Great Debates and Updates in Inflammatory Bowel Diseases on October 24, 2011 please contact us:
E-mail us at registration@imedex.com
Call us toll-free at 1-855-276-6855
or
Register Online at http://www.greatdebatesinibd.com/2012/index.asp
European Perspectives in Lung Cancer
13th EUROPEAN CONGRESS: PERSPECTIVES IN LUNG CANCER
Continuing Medical Education Conference
AMSTERDAM, THE NETHERLANDS, November 21, 2011 — Imedex, LLC would like to present the 13th European Congress: Perspectives in Lung Cancer meeting occurring on March 9-10, 2012 at the Amsterdam RAI Convention Centre in Amsterdam, The Netherlands. This target audience for this continuing education opportunity (CME) is medical and radiation oncologists, thoracic surgeons, pulmonologists, physicians in- training and other healthcare professionals in active clinical practice interested and/or involved in the management of patients with thoracic cancer. With nearly 1,000 physicians, nurses, and other healthcare professionals attending the Perspectives in Lung Cancer conference annually, this oncology CME opportunity is one that should not be missed!
This continuing medical education opportunity will feature an interactive format that will allow speakers and audience members the ability to exchange information through a “hands-on” computerized speaker-audience interaction system. Participants will be able to answer multiple-choice questions and the answers will be calculated and projected on a screen in tabular or graphic form for all to see. This system allows for attendees from diverse disciplines to see differing opinions and compare consensus between the speakers and each other.
After successful completion of this oncology CME opportunity, participants should be able to:
• Evaluate the use of biomarkers for the molecular diagnosis of lung cancer and to predict the efficacy of targeted agents
• Describe and evaluate emerging early detection strategies for lung cancer in Europe
• Compare and contrast invasive versus non-invasive (MRI, CT, PET) procedures in the staging of lung cancer
• Discuss issues and controversies related to the evolving treatment paradigms in front line metastatic NSCLC
• Examine the role of radiotherapy and emerging radiotherapeutic techniques in lung cancer
• Summarize the clinical use of systemic therapies in early-stage lung cancer treatment and incorporate them into practice
• Describe new agents in the treatment of thoracic malignancies, and increase the frequency with which biologically distinct patients are enrolled into appropriate clinical trials
• Analyze the current therapeutic management of mesothelioma and unique populations of patients with thoracic malignancies throughout Europe
For more information about this exciting oncology cme and to register for the 13th European Congress: Perspectives in Lung Cancer on March 9-10, 2012 in Amsterdam, The Netherlands at the Amsterdam RAI Convention Centre
Email us at registration@imedex.com
Call us toll-free at +1 (855) 276 6855
or
Online at http://perspectivesinlungcancer.com
Early registration ends on January 12, 2012.
8th European Congress on Hematologic Malignancies: From Clinical Science to Clinical Practice
8th European Congress on Hematologic Malignancies
From Clinical Science to Clinical Practice
Continuing Medical Education Conference
AMSTERDAM, THE NETHERLANDS, November 21,
2011 — Imedex, LLC would like to present the 8th European Congress on Hematologic Malignancies: From Clinical Science to Clinical Practice conference occurring from February 24-26, 2012 in Amsterdam, The Netherlands. This continuing medical education (CME) meeting has a target audience of hematologists, oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians’ assistants, etc.) involved and/or interested in the therapeutic management of patients with hematologic malignancies, including multiple myeloma, chronic lymphocytic leukemia, and Hodgkin’s and non-Hodgkin lymphomas.
This online hematologic CME opportunity will provide a forum to review state-of-the-art and present new data, as well as give attendees the opportunity to exchange ideas with world-renowned opinion leaders in the field. The Congress encompasses hematologic malignancies, including myeloma, lymphoma, and leukemia, as well as discussions on screening, diagnosis and the latest management options.
Upon completion of this oncology CME opportunity, participants should be able to:
• Have increased awareness/knowledge regarding:
• The evolving role of transplantation in managing hematologic malignancies
• The changing role of radiation therapy in treating hematologic malignancies
• Have increased confidence in their ability to:
• Incorporate latest data into treatment plans for newly diagnosed hematologic malignancies
• Apply novel agents and strategies to treatment of relapsed and/or refractory disease
• Increase the frequency (compared with current level) which with they plan to:
• Use prognostic tools such as imaging, cytogenetics, and risk stratification to guide treatment decisions for patients with hematologic malignancies
• Recommend maintenance therapy for appropriate patients with hematologic malignancies
• Enroll patients with difficult-to-treat hematologic malignancies in clinical trials of novel agents
This online meeting will be broadcasted from Amsterdam February 24-26, 2012.
For more information and to register for the 8th European Congress on Hematologic Malignancies: From Clinical Science to Clinical Practice on February 24-26, 2012 in Amsterdam, The Netherlands please contact us:
E-mail us at registration@imedex.com
Call us at +1 (678) 242 0906
or
Register Online at http://www.europeanhematologicmalignancies.com/2012/index.asp
18th Annual NOCR Meeting Feb 9-11, 2012
18th Annual Network of Oncology Clinicians and Researchers (NOCR) Meeting in Los Vegas at Caesar’s Palace on February 9-11, 2012
Oncology Continuing Medical Education Opportunity
Las Vegas, Nevada, November 9, 2011 – Imedex, LLC would like to present the 18th Annual Network of Oncology Clinicians and Researchers (NOCR) Meeting occurring on February 9-11, 2012 at Caesar’s Palace in Las Vegas, Nevada. This continuing medical education (CME) activity is specifically designed for oncologists, hematologists, and other healthcare professionals (including oncology nurses and pharmacists) interested and/or involved in the care of patients with cancer.
Established in 1993, the Network for Oncology Clinicians and Researchers (NOCR) is a proprietary, self-registered network of over 30,000 oncology healthcare professionals who routinely utilize educational offerings developed by Imedex. The Annual NOCR Meeting was created in 1994 to bring community-based oncologists and their practice teams together with a world-renowned faculty for an oncology CME event where pivotal new research findings and the latest developments in cancer treatment strategies are translated into practical, actionable continuing medical education.
Attending oncologists will participate in clinical case and panel discussions, debates, and Meet the Expert sessions for exchanging the latest information on the diagnosis and management of solid tumors and hematologic malignancies. Some new additions made to the 2012 conference will include discussions on sarcoma and GIST, cutting-edge research in melanoma, and a special session on managing women’s issues in oncology. The concurrent half-day workshops on oncology symptom management and lymphoma-myeloma will be a recurring feature in this oncology CME meeting.
The meeting will take place on Friday, February 9th, 20112, through February 11th, 2012. The meeting will kick off on Friday with registration beginning at 3:30 pm MST. For the remainder of the day, physicians will have their choice of two sessions: Oncology Symptom Management Workshop or Lymphoma-Myeloma Update. On Saturday, physicians will attend four sessions. Session topics include: Women’s Issues, Genitourinary Malignancies, Gastrointestinal Malignancies, and Melanoma. Saturday’s agenda includes three sessions discussing Lung Cancer, Uncommon Malignancies, and Myeloid Malignancies and Chronic Lymphocytic Leukemia.
For more information and to register for The 18th Annual Network of Oncology Clinicians and Researchers (NOCR) Oncology CME Meeting on February 9th-11, 2012 in Las Vegas, Nevada at Caesar’s Palace please contact us:
E-mail us at registration@imedex.com
Call us toll-free at 1-855-276-6855
or
Register Online at http://www.nocrannualmeeting.com
A special discount is available for those who register their entire practice team.
For event updates, and more information about this exciting oncology cme event connect with us! Find us on:
Facebook at http://www.facebook.com/NOCRMeeting
Twitter @NOCRoncologycme
For more Imedex events and updates, visit our blog at http://oncologycme.tumblr.com or go to http://www.imedex.com
